Impact of Hyperferritinemia on the Outcome of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies
Barba, Pere (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Valcárcel, David (Hospital Universitari Vall d'Hebron)
Pérez-Simón, José Antonio (Universitat Autònoma de Barcelona)
Fernandez Aviles, Francesc (Hospital Clínic i Provincial de Barcelona)
Piñana, José Luis (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau)
López-Anglada, Lucía (Universitat Autònoma de Barcelona)
Rovira, Montserrat (Hospital Clínic i Provincial de Barcelona)
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau)
Novelli, Silvana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Carreras, Enric (Hospital Clínic i Provincial de Barcelona)
López Corral, Lucia (Universitat Autònoma de Barcelona)
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2013
Abstract:	Hyperferritinemia has been associated with adverse outcomes after allogeneic hematopoietic cell transplantation (allo-HCT) with myeloablative conditioning. However, its characteristics and impact on the outcome in the reduced-intensity conditioning (RIC) and in the lymphoid malignancy settings are far from clear. The study includes 201 adult patients undergoing allo-HCT with RIC (allo-RIC) for lymphoid malignancies with a median follow-up for survivors of 52 months (range, 3 to 123). Median serum ferritin level at allo-RIC was 379 ng/mL (range, 4 to 10,790). In the multivariate analysis, patients with hyperferritinemia at transplantation (>399 ng/mL) showed lower 4-year overall survival (hazard ratio [HR], 1. 8 [95% confidence interval {CI}, 1. 2 to 2. 8]; P =. 008), higher nonrelapse mortality (NRM) (HR, 1. 8 [95% CI, 1. 1 to 3. 2]; P =. 03), and higher infection-related mortality (HR, 2. 3 [95% CI, 1. 1 to 4. 8]; P =. 02) than patients without hyperferritinemia. Neutrophil and platelet engraftment and 100-day NRM were similar between both groups. The adverse outcome associated with hyperferritinemia seemed higher in patients without major comorbidities and was not influenced by the elevation of acute phase reactants. Our results indicate that high ferritin levels at HCT are associated with an adverse outcome after allo-RIC in patients with lymphoid malignancies. © 2013 American Society for Blood and Marrow Transplantation.
Grants:	Ministerio de Sanidad y Consumo CM06/00139
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Ferritin ; HCT comorbidity index ; Hematopoietic cell transplantation ; Lymphoma ; Reduced-intensity conditioning ; RIC
Published in:	Biology of blood and marrow transplantation, Vol. 19 Núm. 4 (april 2013) , p. 597-601, ISSN 1523-6536

DOI: 10.1016/j.bbmt.2012.12.018
PMID: 23305680

5 p, 234.0 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles